Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalytic Asymmetric Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103421854A reveals a green enzymatic route for Duloxetine intermediates, offering high purity and reduced solvent waste for pharmaceutical supply chains.
Novel biocatalytic synthesis ensures high optical purity for alpha-lipoic acid production. Cost-effective and scalable pharmaceutical intermediate manufacturing solution.
Patent CN105316250B reveals Empedobacter brevis ZJUY-1401 for high-purity chiral alcohol synthesis. Offers significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Novel biocatalytic route for chiral pyrrolidine intermediates. High yield, mild conditions, cost-effective supply for Trk inhibitor manufacturing.
Patent CN101864370A details a high-purity yeast strain method for R-3-quinuclidinol. Discover cost-effective, scalable chiral intermediate solutions for global supply chains.
Patent CN101240299B enables high-purity optically active alcohols via yeast catalysis. Enhances supply chain reliability and reduces manufacturing costs significantly.
Patent CN101407780B details a novel site-directed mutagenesis method for producing high-purity (R)-phenylethylene glycol, offering significant cost and supply chain advantages.
Patent CN101857887B enables high-purity aryl alcohol production. Reduced reaction time and cofactor costs ensure reliable supply chain performance.
Patent CN105777546B offers high yield enzymatic route. Reduces cost and improves supply chain reliability for pharmaceutical intermediates globally.
Patent CN107118986A reveals biocatalytic route for high-purity chiral intermediates. Offers significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN101260415A reveals biocatalytic route for chiral intermediates. Offers supply chain stability and cost efficiency for pharmaceutical manufacturing.
Patent CN107881202A enables high-purity levonorgestrel intermediate production. Biocatalysis ensures supply chain stability and cost efficiency for pharmaceutical manufacturers.
Patent CN104263768A reveals Candida biocatalysis for chiral esters. Offers high yield and ee. Reliable supply chain and cost reduction for pharmaceutical manufacturing.
Patent CN101993828B details a dual-enzyme system for (S)-phenyl glycol. Achieve 100% e.e. and reduced manufacturing costs with scalable biocatalysis.
Patent CN104846025A details enzymatic synthesis of chiral intermediates. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN107794282B reveals a high-yield biocatalytic route for Crizotinib intermediates using Geotrichum candidum, offering superior purity and cost efficiency for API manufacturing.
Patent CN102925500A enables high-purity chiral ester synthesis via yeast biocatalysis, offering cost-effective and scalable pharmaceutical intermediate solutions for global supply chains.
Patent CN104232696A reveals biocatalytic method for high-purity chiral alcohol. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN112176019B details a high-yield biocatalytic route for (R)-1-(3-trifluoromethylphenyl) ethanol using recombinant E. coli and deep eutectic solvents, ensuring >99.9% e.e. and scalable production for neuroprotective intermediates.
Patent CN103773724B reveals biocatalytic route for high-purity chiral alcohol. Enhances supply chain reliability and reduces manufacturing costs significantly.